share_log

Insiders Buying Outlook Therapeutics And 2 Other Stocks

Insiders Buying Outlook Therapeutics And 2 Other Stocks

业内人士购买Outlook Therapeutics和其他2只
Benzinga ·  04/01 10:46

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

尽管周四美国股市收盘涨跌互现,但仍有一些值得注意的内幕交易。

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

当内部人士购买股票时,这表明他们对公司前景充满信心,或者他们认为股票很划算。无论哪种方式,这都预示着做多该股的机会。不应将内幕购买视为做出投资或交易决策的唯一指标。充其量,它可以为购买决定提供信心。

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

以下是最近一些值得注意的内幕收购。欲了解更多,请查看 本辛加的内幕交易 平台。

CION Investment

CION 投资

  • The Trade: CION Investment Corporation (NYSE:CION) Co-Chairman & Co-CEO Mark Gatto acquired a total of 1,150 shares an average price of $11.02. To acquire these shares, it cost around $12,673.
  • What's Happening: On March 14, CION Invt posted downbeat quarterly earnings
  • What CION Investment Does: CION Investment is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company.
  • 贸易:CION投资公司(纽约证券交易所代码:CION)联席董事长兼联席首席执行官马克·加托 共收购了 1,150 股股票 平均价格为11.02美元。收购这些股票的成本约为12,673美元。
  • 发生了什么:3月14日,CION Invt公布了悲观的季度收益
  • CION Investment做什么:CION Investment是一家外部管理、非多元化的封闭式管理投资公司,已选择作为业务发展公司接受监管。

Outlook Therapeutics

Outlook 疗法

  • The Trade: Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin acquired a total of 1,881 shares at an average price of $11.82. To acquire these shares, it cost around $22,242.
  • What's Happening: On March 27, BTIG upgraded the stock from Neutral to Buy and announced a $50 price target.
  • What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
  • 交易:Outlook Therapeutics, Inc.(纳斯达克股票代码:OTLK)董事耶赞·芒特·哈达丁共收购了1,881股股票,平均价格为11.82美元。收购这些股票的成本约为22,242美元。
  • 发生了什么:3月27日,BTIG将该股从中性上调至买入,并宣布了50美元的目标股价。
  • Outlook Therapeutics做什么:Outlook Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发和商业化适用于各种眼科适应症的单克隆抗体或单克隆抗体 ONS-5010。

Don't forget to check out our premarket coverage here

别忘了在这里查看我们的上市前报道

Rocket Companies

火箭公司

  • The Trade: Rocket Companies, Inc. (NYSE:RKT) Director Matthew Rizik bought a total of 301 shares at an average price of $14.57. To acquire these shares, it cost around $4,386.
  • What's Happening: On March 18, B of A Securities analyst Mihir Bhatia maintained Rocket Companies with an Underperform and raised the price target from $7 to $8.
  • What Rocket Companies Does: Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit.
  • 贸易:火箭公司(纽约证券交易所代码:RKT)董事马修·里齐克 共购买了 301 股股票 平均价格为14.57美元。收购这些股票的成本约为4,386美元。
  • 发生了什么:3月18日,B of A Securities分析师米希尔·巴蒂亚维持了火箭公司的表现不佳,并将目标股价从7美元上调至8美元。
  • 火箭公司做什么:火箭公司是一家金融服务公司,最初成立于1985年,名为Rock Financial,目前总部设在底特律。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发